Latest Headlines

Latest Headlines

HIV therapeutic vaccine shows promise

As a new wave of interest in HIV therapeutic vaccines hits the biotech world, a team of Spanish researchers claims to have developed such a vaccine that temporarily halts growth of the HIV virus in patients.

Combating HIV: The future of therapeutic vaccines

HIV patients rely on a bevy of drugs to keep their illness under control, sticking to a strict regimen to maintain health. But let's face it: Adherence is a challenge and drug side effects can be rough. Enter HIV therapeutic vaccines. Read more >>

Norway's Bionor snags $1.7 million for HIV vaccine research

Norway's Bionor Pharma landed $1.7 million from the Research Council of Norway's Globvac program to learn more about what role a vaccine can play in eliminating HIV.

Bionor's new HIV vaccine moves into clinical trials

Bionor's latest HIV vaccine, Vacc-C5, is ready to go into therapeutic clinical trials at Oslo University Hospital.

Nasal HIV vax safe, triggers immune response

The therapeutic HIV vaccine that the company nearly shelved in October 2011, Bionor's Vacc-4X, was safe given nasally to HIV-positive patients also on antiretrovirals.

Bionor HIV vaccine lowers viral load, ART need

Norwegian biotech Bionor Pharma has released results from a study of its therapeutic HIV vaccine, Vacc-4x. After initially planning to shelve the vaccine last October, the company is now plotting